# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA971312 | F | Cytotoxicity against human NCI-H2228 cells assessed as fraction of viable cells after 72 hrs relative to control | Homo sapiens | 13 | ALA1149823 | cell-based format | Scientific Literature | |
2. | ALA1646585 | F | Growth inhibition of human NCI-H2228 cells assessed as ATP level after 96 hrs by CellTiter-Glo assay | Homo sapiens | 1 | ALA1641579 | cell-based format | Scientific Literature | |
3. | ALA1781785 | F | Antitumor activity against human NCI-H2228 cells expressing EML4-ALK xenografted in SCID mouse assessed as reduction of tumor volume administered as po qd for 11 days | Homo sapiens | 1 | ALA1777813 | organism-based format | Scientific Literature | |
4. | ALA1781787 | F | Antitumor activity against human NCI-H2228 cells expressing EML4-ALK xenografted in SCID mouse assessed as tumor regression at 0.2 to 20 mg/kg, po qd for 11 days | Homo sapiens | 1 | ALA1777813 | organism-based format | Scientific Literature | |
5. | ALA1942693 | F | Antitumor activity against human NCI-H2228 cells expressing EML4-ALK xenografted mouse model assessed as tumor growth inhibition at 20 mg/kg, po | Homo sapiens | 1 | ALA1938232 | organism-based format | Scientific Literature | |
6. | ALA2049280 | F | Cytotoxicity against human NCI-H2228 cells after 72 hrs by MTT assay | Homo sapiens | 1 | ALA2046280 | cell-based format | Scientific Literature | |
7. | ALA2363513 | F | SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay. | Homo sapiens | 98 | ALA1201861 | cell-based format | Sanger Institute Genomics of Drug Sensitivity in Cancer | |
8. | ALA2406422 | F | Antitumor activity against human NCI-H2228 cells expressing EML4-ALK fusion gene xenografted in rat assessed as tumor regression | Homo sapiens | 1 | ALA2401656 | cell-based format | Scientific Literature | |
9. | ALA2405335 | F | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as complete tumor regression at 25 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | Homo sapiens | 1 | ALA2401692 | organism-based format | Scientific Literature | |
10. | ALA2405336 | F | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition factor at 10 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | Homo sapiens | 1 | ALA2401692 | organism-based format | Scientific Literature | |
11. | ALA2405337 | F | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition factor at 5 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | Homo sapiens | 1 | ALA2401692 | organism-based format | Scientific Literature | |
12. | ALA2405338 | F | Antitumor activity against human NCI-H2228 cells xenografted in po dosed Rowett nude rat assessed as tumor growth inhibition administered for 14 days measured 7 to 72 hrs post dosing | Homo sapiens | 1 | ALA2401692 | organism-based format | Scientific Literature | |
13. | ALA3129269 | F | Ratio of crizotinib IC50 to compound IC50 for human NCI-H2228 cells | Homo sapiens | 1 | ALA3124869 | cell-based format | Scientific Literature | |
14. | ALA3129278 | F | Inhibition of ALK-fusion driven cell proliferation in human NCI-H2228 cells after 72 hrs by CellTiter Glo assay | Homo sapiens | 2 | ALA3124869 | cell-based format | Scientific Literature | |
15. | ALA3413670 | F | Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay | Homo sapiens | 12 | ALA3407415 | cell-based format | Scientific Literature | |
16. | ALA3413671 | F | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition at 36.24 mg/kg/day, po administered for 14 days measured on day 15 | Homo sapiens | 1 | ALA3407415 | organism-based format | Scientific Literature | |
17. | ALA3413672 | F | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition at 38.28 mg/kg/day, po administered for 14 days measured on day 15 relative to vehicle-treated control | Homo sapiens | 1 | ALA3407415 | organism-based format | Scientific Literature | |
18. | ALA3413673 | F | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition at 30 mg/kg/day, po administered for 14 days measured on day 15 | Homo sapiens | 1 | ALA3407415 | organism-based format | Scientific Literature | |
19. | ALA3607643 | F | Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation incubated for 96 hrs by cell-titer-Glo assay | Homo sapiens | 26 | ALA3603807 | cell-based format | Scientific Literature | |
20. | ALA3607645 | F | Antitumor activity activity against human NCI-H2228 cells xenografted in Balb/c mouse EML4-ALK NSCLC model assessed as reduction in tumor growth at 3 to 30 mg/kg, po qd for 2 weeks | Homo sapiens | 1 | ALA3603807 | organism-based format | Scientific Literature |